Asmacure Ltée

About Asmacure Ltée

Asmacure Ltée is a clinical-stage biopharmaceutical company headquartered in Quebec, Canada, that is concentrated on developing novel treatments for pulmonary diseases. The company was founded by Dr. Yvon Cormier, a seasoned pneumologist with an extensive background in both clinical practice and research at the Quebec Heart and Lung Institute (IUCPQ), an institution affiliated with Laval University. Dr. Cormier's research has been a cornerstone of the company's scientific direction, where he also serves as the Chief Medical Officer.

The company's primary focus is the development of its lead compound, ASM-024, a new molecular entity designed to treat asthma and other inflammatory respiratory conditions. Asmacure's business model is centered on the research and development of proprietary compounds that target cholinergic receptors, aiming to bring new therapeutic options to market. A significant financial milestone was achieved on May 8, 2007, when the company secured US$9 million in a Series A financing round from investors including Fonds Bio-Innovation, Innovatech Québec Chaudière-Appalaches, and Domain Associates. This funding was instrumental in advancing ASM-024 through preclinical and into clinical development.

ASM-024 distinguishes itself through a multi-functional mechanism of action that targets both nicotinic and muscarinic receptors. This dual action provides anti-inflammatory effects, bronchoprotection, and smooth muscle relaxation, as demonstrated in preclinical asthma models. The therapeutic is being developed as a dry powder for inhalation (DPI), a preferred dosage form for pulmonary products that allows for more optimal dosing and greater lung deposition. Clinical trials have been initiated to evaluate the safety and efficacy of the ASM-024 DPI in patients with moderate asthma and Chronic Obstructive Pulmonary Disease (COPD). The intellectual property for this technology is protected by patents in key markets, including the United States and Japan.